The global proton pump inhibitors market is estimated to grow at a significant CAGR during the forecast period. Many researchers have found that proton pump inhibitors have raised the risk of COVID-19 in patients taking these medications. The researchers of the American Journal of Gastroenterology, in 2020, conducted research in which more than 55,000 people taking proton pump inhibitors participated, out of which 3,476 said that they had tested positive for COVID-19. This factor is projected to impact the market growth as the patients going through PPI therapy are advised to consume fewer medications and avoid these medications unless it is an emergency. Thus, a negative impact due to COVID-19 on this market can be observed.
A full report of PPI Market is available at: https://www.omrglobal.com/industry-reports/ppi-market
Proton pump inhibitors are the gold standard medication for gastroesophageal reflux disease (GERD), and the growing prevalence of GERD and the increasing acceptance of novel drug delivery systems are the two most significant factors propelling the growth of the market.
GERD has become a common lifestyle complication among populations in developed and developing regions. Also, for instance, the US National Library of Medicine (NCBI) disclosed a report in October 2018, which stated that roughly 8.7–25.8% of the population in Europe, 2.6–7.6% in East Asia, 18.2–27.2% in North America, 11.1% in Australia, and 25.0% in South America had gastroesophageal reflux disease (GERD) in that year. Also, as per the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, globally, there were 9382 (8183 to 10700) cases per 100,000 population in 2019, and 708 million (624 to 785) people of the world reported GERD in 2019.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/ppi-market
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Type
o By Disease Indication
o By Distribution Channel
- Competitive Landscape: AstraZeneca, Bayer AG, Cadila Pharmaceuticals, GlaxoSmithKline PLC, Johnson & Johnson.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global PPI Market by Region
By Type
- Omeprazole
- Pantaprazole
- Rabeprazole
- Dexlansoprazole
- Lansoprazole
- Others
By Disease Indication
- Ulcers
- Gastroesophageal Reflux Disease
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.
